HC Wainwright Reiterates “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA)

HC Wainwright reiterated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Monday morning,Benzinga reports. They currently have a $45.00 price objective on the stock. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($2.24) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

Other research analysts have also recently issued research reports about the stock. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price target on the stock. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective on the stock. Leerink Partners assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 target price for the company. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, TD Cowen started coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating for the company. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Stock Performance

ORKA opened at $20.26 on Monday. The business has a 50 day simple moving average of $25.67. The stock has a market capitalization of $709.08 million, a P/E ratio of -3.24 and a beta of 0.87. Oruka Therapeutics has a 12-month low of $18.20 and a 12-month high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently modified their holdings of ORKA. FMR LLC purchased a new position in Oruka Therapeutics during the third quarter valued at $114,763,000. RTW Investments LP purchased a new stake in Oruka Therapeutics in the 3rd quarter worth $45,359,000. Franklin Resources Inc. bought a new position in shares of Oruka Therapeutics during the 3rd quarter valued at about $17,661,000. Braidwell LP purchased a new position in shares of Oruka Therapeutics during the third quarter valued at about $12,640,000. Finally, Great Point Partners LLC bought a new stake in shares of Oruka Therapeutics in the third quarter worth about $12,614,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.